Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Stock Information for Veru Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veru Inc.

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.